NEWSROOM

GeNeuro Regains Worldwide Rights ex US and Japan to GNbAC1 in Multiple Sclerosis from Servier

18 / 09 / 2018Press release

Servier finalizes acquisition of Shire’s oncology branch

31 / 08 / 2018Press release

Servier group appoints David K. Lee as CEO of Servier Pharmaceuticals (US)

16 / 07 / 2018Press release

Servier and Galapagos announce start of global ROCCELLA Phase 2 clinical trial with S201086/GLPG1972 in osteoarthritis

27 / 06 / 2018Press release

WeHealth by Servier joins forces with Peter Sheehan Diabetes Care Foundation in the fight against diabetes

12 / 06 / 2018Press release

Servier backs the research project of an American startup in the field of oncology

26 / 04 / 2018Press release

Servier acquires Shire’s Oncology business to gain direct commercial access in the US

16 / 04 / 2018Press release

WeHealth by Servier and UCSF form partnership to identify most promosing e-health startups

12 / 04 / 2018Press release

Servier and Scandicure enter into agreement to conduct research in the field of metabolic diseases

03 / 04 / 2018Press release

GeNeuro and Servier announce successful 12-month results in neuroprotection for Phase 2b CHANGE-MS Study with GNbAC1 in Multiple Sclerosis

26 / 03 / 2018Press release

WeHealth by Servier and DEEPLINK MEDICAL sign a partnership to develop a new e-health solution

13 / 03 / 2018Press release

Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the 44th EBMT annual meeting

09 / 03 / 2018Press release